Literature DB >> 9703174

Distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome.

P Maddison1, J Newsom-Davis, K R Mills.   

Abstract

OBJECTIVE: To assess the distribution of electrophysiological abnormality in Lambert-Eaton myasthenic syndrome (LEMS) to identify the most sensitive muscle to use in routine examination.
METHODS: Surface recorded compound muscle action potential (CMAP) amplitudes were made from abductor digiti minimi, abductor pollicis brevis, anconeus, biceps brachii, and trapezius in 10 patients with LEMS. The effect of 3,4-diaminopyridine (3,4-DAP) was recorded in each muscle in nine patients. CMAP amplitudes were measured at rest and immediately after 10 seconds maximal voluntary contraction in each muscle. Values were compared with results obtained from 12 healthy controls.
RESULTS: Resting CMAP amplitudes were reduced in at least one muscle in all patients compared with controls, most markedly in abductor digiti minimi and anconeus. The administration of 3,4-DAP resulted in significantly improved resting CMAP amplitudes in trapezius only. After maximal voluntary muscle contraction, characteristic increments in CMAP amplitude of over 100% above resting values were seen in abductor digiti minimi and abductor pollicis brevis in seven patients, anconeus and biceps brachii in five patients. No patient had this level of increment in trapezius.
CONCLUSION: Despite predominantly proximal limb weakness seen clinically in patients with LEMS, the most sensitive muscles for detecting characteristic electrophysiological abnormalities of low resting CMAP amplitude and increment of over 100% after 10 seconds maximal voluntary contraction are abductor digiti minimi, abductor pollicis brevis, and anconeus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703174      PMCID: PMC2170198          DOI: 10.1136/jnnp.65.2.213

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  22 in total

1.  Quantal components of end-plate potentials in the myasthenic syndrome.

Authors:  E H Lambert; D Elmqvist
Journal:  Ann N Y Acad Sci       Date:  1971-09-15       Impact factor: 5.691

2.  Electrophysiological and clinical correlations in the Lambert-Eaton myasthenic syndrome.

Authors:  S J Oh; D E Kim; R Kuruoglu; J Brooks; G Claussen
Journal:  Muscle Nerve       Date:  1996-07       Impact factor: 3.217

3.  Accessory nerve stimulation in the assessment of myasthenia gravis.

Authors:  F Schumm; M Stöhr
Journal:  Muscle Nerve       Date:  1984-02       Impact factor: 3.217

4.  Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis; N M Murray
Journal:  Neurology       Date:  1984-04       Impact factor: 9.910

5.  Clinical electrophysiology in myasthenia gravis.

Authors:  E Stalberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

6.  Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome.

Authors:  B Lang; J Newsom-Davis; D Wray; A Vincent; N Murray
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

7.  Cancer-associated myasthenic (Eaton-Lambert) syndrome: distribution of abnormality and effect of treatment.

Authors:  D A Ingram; G R Davis; M S Schwartz; M Traub; A C Newland; M Swash
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

8.  Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission.

Authors:  N M Murray; J Newsom-Davis
Journal:  Neurology       Date:  1981-03       Impact factor: 9.910

9.  Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine.

Authors:  H Lundh; O Nilsson; I Rosén
Journal:  Neurology       Date:  1984-10       Impact factor: 9.910

10.  The Lambert-Eaton myasthenic syndrome. A review of 50 cases.

Authors:  J H O'Neill; N M Murray; J Newsom-Davis
Journal:  Brain       Date:  1988-06       Impact factor: 13.501

View more
  7 in total

Review 1.  Italian recommendations for Lambert-Eaton myasthenic syndrome (LEMS) management.

Authors:  A Evoli; R Liguori; A Romani; R Mantegazza; A Di Muzio; B Giometto; E Pegoraro; C Rodolico; M C Vigliani
Journal:  Neurol Sci       Date:  2014-01-31       Impact factor: 3.307

2.  Lambert-Eaton Myasthenic Syndrome.

Authors:  John Newsom-Davis
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.598

3.  Amifampridine safety and efficacy in spinal muscular atrophy ambulatory patients: a randomized, placebo-controlled, crossover phase 2 trial.

Authors:  Silvia Bonanno; Riccardo Giossi; Riccardo Zanin; Valentina Porcelli; Claudio Iannacone; Giovanni Baranello; Gary Ingenito; Stanley Iyadurai; Zorica Stevic; Stojan Peric; Lorenzo Maggi
Journal:  J Neurol       Date:  2022-06-28       Impact factor: 6.682

4.  Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer.

Authors:  P Maddison; B Lang; K Mills; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-02       Impact factor: 10.154

5.  Neuromuscular junctional disorders.

Authors:  A S Girija; V V Ashraf
Journal:  Indian J Pediatr       Date:  2008-08-21       Impact factor: 1.967

6.  Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer.

Authors:  Lidia Sabater; Romana Höftberger; Anna Boronat; Albert Saiz; Josep Dalmau; Francesc Graus
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

7.  Clinical and electrophysiological evaluation of myasthenic features in an alpha-dystroglycanopathy cohort (FKRP-predominant).

Authors:  Paloma Gonzalez-Perez; Cheryl Smith; Wendy L Sebetka; Amber Gedlinske; Seth Perlman; Katherine D Mathews
Journal:  Neuromuscul Disord       Date:  2020-01-25       Impact factor: 4.296

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.